PROUROKINASE-ANNEXIN-V CHIMERAS - CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF RECOMBINANT PROTEINS

被引:58
作者
TAIT, JF
ENGELHARDT, S
SMITH, C
FUJIKAWA, K
机构
[1] UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA
[2] UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA
关键词
D O I
10.1074/jbc.270.37.21594
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Annexin V is a human protein that binds with high affinity to the abundant phosphatidylserine molecules exposed on activated platelets and accumulates selectively in thrombi after intravenous administration in animal models of arterial thrombosis. We designed two chimeras that use annexin V as a means to target thrombolytic agents to platelet-containing thrombi: prourokinase (1-411)-annexin V (1-320); and prourokinase (144-411)-annexin V (1-320) (amino acid numbers of parent proteins given in parentheses). Chimeras were produced by cytoplasmic expression in Escherichia coli, refolded, and purified in single-chain form. Both chimeras had the same specific activity as annexin V in binding to cell membranes containing exposed phosphatidylserine. After activation with plasmin, both chimeras had specific amidolytic activity similar to that of urokinase. Both chimeras activated plasminogen in vitro with kinetic parameters similar to those for urokinase, and both showed full activity compared to urokinase in an assay of clot lysis in vitro. This study shows the feasibility of producing chimeric plasminogen activators in which annexin V provides the thrombus-targeting component; although not yet tested in vivo, such chimeras may have advantages over antibody-based targeting agents.
引用
收藏
页码:21594 / 21599
页数:6
相关论文
共 41 条
[1]  
ANDERSON HV, 1993, NEW ENGL J MED, V329, P703
[2]  
ANDREE HAM, 1990, J BIOL CHEM, V265, P4923
[3]   CHANGES IN MEMBRANE PHOSPHOLIPID DISTRIBUTION DURING PLATELET ACTIVATION [J].
BEVERS, EM ;
COMFURIUS, P ;
ZWAAL, RFA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 736 (01) :57-66
[4]  
BEVERS EM, 1991, BLOOD REV, V5, P147
[5]   ANTIBODY-DIRECTED UROKINASE - A SPECIFIC FIBRINOLYTIC AGENT [J].
BODE, C ;
MATSUEDA, GR ;
HUI, KY ;
HABER, E .
SCIENCE, 1985, 229 (4715) :765-767
[6]   PLATELET-TARGETED FIBRINOLYSIS ENHANCES CLOT LYSIS AND INHIBITS PLATELET-AGGREGATION [J].
BODE, C ;
MEINHARDT, G ;
RUNGE, MS ;
FREITAG, M ;
NORDT, T ;
ARENS, M ;
NEWELL, JB ;
KUBLER, W ;
HABER, E .
CIRCULATION, 1991, 84 (02) :805-813
[7]   CONJUGATION TO ANTIFIBRIN FAB' ENHANCES FIBRINOLYTIC POTENCY OF SINGLE-CHAIN UROKINASE PLASMINOGEN-ACTIVATOR [J].
BODE, C ;
RUNGE, MS ;
SCHONERMARK, S ;
EBERLE, T ;
NEWELL, JB ;
KUBLER, W ;
HABER, E .
CIRCULATION, 1990, 81 (06) :1974-1980
[8]   TOWARDS IMPROVED THROMBOLYTIC THERAPY [J].
COLLEN, D .
LANCET, 1993, 342 (8862) :34-36
[9]   RAT ANNEXIN-V CRYSTAL-STRUCTURE - CA2+-INDUCED CONFORMATIONAL-CHANGES [J].
CONCHA, NO ;
HEAD, JF ;
KAETZEL, MA ;
DEDMAN, JR ;
SEATON, BA .
SCIENCE, 1993, 261 (5126) :1321-1324
[10]   ORGANIZATION OF THE HUMAN ANNEXIN-V (ANX5) GENE [J].
COOKSON, BT ;
ENGELHARDT, S ;
SMITH, C ;
BAMFORD, HA ;
PROCHAZKA, M ;
TAIT, JF .
GENOMICS, 1994, 20 (03) :463-467